PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

Inclusion Criteria

• •Patient must have malignancy with metastatic or recurrent diseases.
• •Patient must have a minimum of thirteen days period elapsed from any previous chemotherapy or radiotherapy and all treatment-related toxicities subsided.
• •Patient must have at least 2 courses of chemotherapy treatment left, and a minimum of 13 days between the administration of the last dose of the chemotherapy with PG2 and the start of the next course of chemotherapy.
• •Performance status is 0-2 by ECOG scale.
• •Patient's compliance and geographic proximity that allow adequate follow up.
• •Adequate bone marrow function before the chemotherapy
• •Adequate liver and renal function before the chemotherapy
• •Written informed consent from patients
• •Woman with childbearing potential should use contraception method through the whole PG2 treatment course.
• •After the previous course of chemotherapy, the nadir of WBC dropped between 1000 to 3000/ mm3 (for phase II only).